All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Gabriele Magliano, Università Cattolica del Sacro Cuore, Rome, IT. We asked, What is the outcome of transplantation in fit patients over 64 years?
What is the outcome of transplantation in fit patients over 64 years?
In this video, Magliano discusses allogeneic hematopoietic stem cell transplantation outcomes for fit patients with AML over the age of 64. He explains that nowadays, age is not the main factor influencing whether patients achieve complete remission, but rather their overall clinical presentation. Magliano outlines the results of recent cohort trials on geriatric patients with AML and remains hopeful for future therapies.
Evaluating predictive factors for post-HSCT survival in secondary AML
Patients with secondary acute myeloid leukemia (sAML) have poor clinical outcomes, even after intensive chemotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT)...
COVID-19 vaccination for hematopoietic stem cell transplant patients
The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular, patients with hematologic malignancies have been...
Subscribe to get the best content related to AML delivered to your inbox